BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a biopharmaceutical company that develops medicines in neuroscience, alongside its wholly owned subsidiary OnkosXcel Therapeutics, which focuses on immuno-oncology. The company utilizes a proprietary artificial intelligence platform designed to identify new therapeutic indications from existing approved drugs or clinical candidates to treat disorders with unmet medical needs. Its commercialized product is IGALMI, a sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults. Its clinical pipeline includes BXCL501 for acute agitation across neuropsychiatric conditions and BXCL701 for various aggressive tumors. Target customers encompass healthcare providers, hospitals, integrated delivery networks, and patients requiring agitation management.

The company operates primarily within the United States, commercializing IGALMI through domestic distribution channels while evaluating potential commercial partnerships and third-party collaborations for prospective international distribution. The provided text mentions no international regulatory filings, geographic operational hubs, or specific corporate headquarters location.

Summary of the business section of BioXcel Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“We completed these additional restructuring actions to further reduce the workforce by 50%, ending the year ended December 31, 2024 with 37 full-time employees.”